IP Library Granted Patent US 9,676,842
Granted Patent B2
US 9,676,842 · App. 14/301,872 · Granted Jun 13, 2017

Anti-properdin antibodies

Inventor: Rekha Bansal (Twinsburg, OH)
Assignee: NOVELMED THERAPEUTICS, INC.
C07K16/18A61K2039/505C07K2317/34C07K2317/54C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,676,842
App. No.
14/301,872
Granted
Jun 13, 2017
Kind
B2
Abstract

A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.

Claims (5)

1. An isolated anti-properdin antibody or antigen binding fragment thereof that specifically binds to the amino acid sequence of SEQ ID NO: 2 of properdin.

2. The isolated anti-properdin antibody or antigen binding fragment thereof of claim 1 , wherein the anti-properdin antibody is a monoclonal antibody.

3. A composition comprising:

an isolated anti-properdin antibody or antigen binding fragment thereof that specifically binds to the amino acid sequence of SEQ ID NO: 2 of properdin, and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 , wherein the anti-properdin antibody is a monoclonal antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: BANSAL, REKHA
To: NOVELMED THERAPEUTICS, INC.
Reel/Frame 033810/0196 →
Continuity (4)
Continuation 13849092 · Mar 22, 2013
Continuation 12920997
Provisional Application 61033127 · Mar 3, 2008
Related Publication 20140328846A1 · Nov 6, 2014